Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Rises By 332.2%

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 228,200 shares, a growth of 332.2% from the February 13th total of 52,800 shares. Approximately 4.4% of the company’s stock are short sold. Based on an average daily volume of 354,000 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets cut their price target on Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Monday, December 16th.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Geode Capital Management LLC bought a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 33,540 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned 0.62% of Alzamend Neuro as of its most recent filing with the SEC. Institutional investors and hedge funds own 49.61% of the company’s stock.

Alzamend Neuro Stock Down 4.0 %

NASDAQ:ALZN opened at $0.67 on Thursday. Alzamend Neuro has a twelve month low of $0.66 and a twelve month high of $15.06. The business has a 50 day moving average price of $1.04 and a two-hundred day moving average price of $1.40.

Alzamend Neuro (NASDAQ:ALZN) last announced its earnings results on Monday, March 10th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.10. On average, research analysts expect that Alzamend Neuro will post -1.68 EPS for the current year.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.